GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Royalty Pharma PLC (NAS:RPRX) » Definitions » EPS without NRI

Royalty Pharma (Royalty Pharma) EPS without NRI

: $2.00 (TTM As of Dec. 2023)
View and export this data going back to 2020. Start your Free Trial

Royalty Pharma's earnings per share without non-recurring items for the three months ended in Dec. 2023 was $0.83. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was $2.00.

During the past 12 months, Royalty Pharma's average earnings per share (NRI) Growth Rate was 45.70% per year. During the past 3 years, the average earnings per share (NRI) Growth Rate was 30.70% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was -14.50% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Royalty Pharma's EPS without NRI or its related term are showing as below:

RPRX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -39.8   Med: -20   Max: 30.7
Current: 30.7

During the past 7 years, Royalty Pharma's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 30.70% per year. The lowest was -39.80% per year. And the median was -20.00% per year.

RPRX's 3-Year EPS without NRI Growth Rate is ranked better than
79.75% of 1294 companies
in the Biotechnology industry
Industry Median: 4.5 vs RPRX: 30.70

Royalty Pharma's EPS (Diluted) for the three months ended in Dec. 2023 was $1.10. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $2.52.

Royalty Pharma's EPS (Basic) for the three months ended in Dec. 2023 was $1.11. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $2.54.


Royalty Pharma EPS without NRI Historical Data

The historical data trend for Royalty Pharma's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Royalty Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Premium Member Only Premium Member Only 6.30 0.90 1.62 1.38 2.01

Royalty Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS without NRI Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.18 0.71 0.30 0.16 0.83

Competitive Comparison

For the Biotechnology subindustry, Royalty Pharma's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Royalty Pharma PE Ratio without NRI Distribution

For the Biotechnology industry and Healthcare sector, Royalty Pharma's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Royalty Pharma's PE Ratio without NRI falls into.



Royalty Pharma EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Royalty Pharma  (NAS:RPRX) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Royalty Pharma EPS without NRI Related Terms

Thank you for viewing the detailed overview of Royalty Pharma's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Royalty Pharma (Royalty Pharma) Business Description

Traded in Other Exchanges
Address
110 East 59th Street, FL 33, New York, NY, USA, 10022
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Executives
Rory B Riggs director 65 RAILROAD AVE, RIDGEFIELD NJ 07657
Avara Management Ltd 10 percent owner C/O GISEV FAMILY OFFICE SA, CONTRADA DI SASSELLO 2, LUGANO V8 6900
Terrance P. Coyne officer: EVP & CFO C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022
Pablo G. Legorreta director, officer: CEO, Chairman of the Board 110 E 59TH STREET, SUITE 3300, NEW YORK NY 10022
George W. Lloyd officer: EVP, Investments & GC C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022
Marshall Urist officer: EVP, Research & Investments C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022
Mario Germano Giuliani director, 10 percent owner C/O GISEV FAMILY OFFICE SA, CONTRADA DI SASSELLO 2, LUGANO V8 6900
James F. Reddoch officer: EVP, Research & Investments C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022
Nogra Group Sicaf Sif Gg Strategic 10 percent owner C/O NOGRA GROUP SICAF-SIF S.A., 18 AVENUE DE LA PORTE NEUVE, LUXEMBOURG N4 L-2227
Nogra Group Sicaf - Sif S.a. 10 percent owner 18 AVENUE DE LA PORTE NEUVE, LUXEMBOURG N4 L-2227
Catherine M. Engelbert director 110 NORTH CARPENTER STREET, CHICAGO IL 60607
Errol B Desouza director 215 COLLEGE ROAD, PARAMUS NJ 07652
Henry A Fernandez director MSCI INC., 88 PINE STREET, NEW YORK NY 10005
Gregory Norden director 16640 CHESTERFIELD GROVE DRIVE, SUITE 200, CHESTERFIELD MO 63005
Ted W Love director C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080